MUC1 promotes NSCLC progression by regulating ICAM-1-mediated mitochondria transfer from tCAFs to cancer cells.

IF 3.1 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Feifan Ji, Donglian Wang, Jingguang Jin, Jin Zhang, Lingyu Guan
{"title":"MUC1 promotes NSCLC progression by regulating ICAM-1-mediated mitochondria transfer from tCAFs to cancer cells.","authors":"Feifan Ji, Donglian Wang, Jingguang Jin, Jin Zhang, Lingyu Guan","doi":"10.1007/s00210-025-04672-0","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer-associated fibroblasts (tCAFs) promote non-small cell lung cancer (NSCLC) progression through cargo exchange with cancer cells. Mucin 1 (MUC1) initiates actin-mediated cytoskeleton protrusion movement to promote mitochondrial transfer. In this study, we aimed to investigate whether MUC1 regulates mitochondrial transfer from tCAFs to NSCLC cells. The results showed that lung cancer patients with high MUC1 expression had a poor prognosis, and MUC1 protein was significantly enriched in exosomes (EXOs) derived from tCAFs. A549 cells were treated with conditioned medium (CM) or EXOs derived from tCAFs or co-cultured with tCAFs in contact or non-contact ways. Both CM and EXOs promoted the proliferation and invasion and inhibited apoptosis in A549 cells, while MUC1-interfered EXOs inhibited A549 cell proliferation and invasion and induced apoptosis. Meanwhile, non-contact co-culture of tCAFs and A549 cells promoted proliferation, invasion, and colony formation of A549 cells, and contact co-culture further promoted malignant phenotype of A549 cells and enhanced mitochondrial function in A549 cells. Mechanism studies revealed that MUC1 promotes mitochondrial transfer from tCAFs to A549 cells by interacting with intercellular adhesion molecule-1 (ICAM1), promoting malignant phenotype of A549 cells. ICAM1 interference counteracted the effect of EXO protein MUC1 on A549 cells. Finally, lung cancer xenograft tumor models were constructed and found that EXO protein MUC1 promoted lung cancer tumor growth in vivo, while ICAM1 interference inhibited tumor growth. In conclusion, MUC1 is enriched in EXOs derived from tCAFs and promotes NSCLC progression by regulating ICAM1-mediated mitochondria transfer from tCAFs to cancer cells.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-025-04672-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer-associated fibroblasts (tCAFs) promote non-small cell lung cancer (NSCLC) progression through cargo exchange with cancer cells. Mucin 1 (MUC1) initiates actin-mediated cytoskeleton protrusion movement to promote mitochondrial transfer. In this study, we aimed to investigate whether MUC1 regulates mitochondrial transfer from tCAFs to NSCLC cells. The results showed that lung cancer patients with high MUC1 expression had a poor prognosis, and MUC1 protein was significantly enriched in exosomes (EXOs) derived from tCAFs. A549 cells were treated with conditioned medium (CM) or EXOs derived from tCAFs or co-cultured with tCAFs in contact or non-contact ways. Both CM and EXOs promoted the proliferation and invasion and inhibited apoptosis in A549 cells, while MUC1-interfered EXOs inhibited A549 cell proliferation and invasion and induced apoptosis. Meanwhile, non-contact co-culture of tCAFs and A549 cells promoted proliferation, invasion, and colony formation of A549 cells, and contact co-culture further promoted malignant phenotype of A549 cells and enhanced mitochondrial function in A549 cells. Mechanism studies revealed that MUC1 promotes mitochondrial transfer from tCAFs to A549 cells by interacting with intercellular adhesion molecule-1 (ICAM1), promoting malignant phenotype of A549 cells. ICAM1 interference counteracted the effect of EXO protein MUC1 on A549 cells. Finally, lung cancer xenograft tumor models were constructed and found that EXO protein MUC1 promoted lung cancer tumor growth in vivo, while ICAM1 interference inhibited tumor growth. In conclusion, MUC1 is enriched in EXOs derived from tCAFs and promotes NSCLC progression by regulating ICAM1-mediated mitochondria transfer from tCAFs to cancer cells.

MUC1通过调节icam -1介导的线粒体从tcas向癌细胞的转移来促进NSCLC的进展。
癌症相关成纤维细胞(tCAFs)通过与癌细胞的货物交换促进非小细胞肺癌(NSCLC)的进展。Mucin 1 (MUC1)启动肌动蛋白介导的细胞骨架突出运动,促进线粒体转移。在这项研究中,我们旨在研究MUC1是否调节线粒体从tCAFs向NSCLC细胞的转移。结果显示MUC1高表达的肺癌患者预后较差,且MUC1蛋白在tcas衍生的外泌体(EXOs)中显著富集。A549细胞分别用条件培养基(CM)或tCAFs衍生的exo处理,或以接触或非接触方式与tCAFs共培养。CM和EXOs均能促进A549细胞的增殖和侵袭,抑制A549细胞的凋亡,而muc1干扰的EXOs抑制A549细胞的增殖和侵袭,诱导A549细胞的凋亡。同时,tCAFs与A549细胞非接触共培养促进了A549细胞的增殖、侵袭和集落形成,接触共培养进一步促进了A549细胞的恶性表型,增强了A549细胞的线粒体功能。机制研究表明,MUC1通过与细胞间粘附分子-1 (ICAM1)相互作用,促进线粒体从tCAFs向A549细胞转移,促进A549细胞的恶性表型。ICAM1干扰抵消了EXO蛋白MUC1对A549细胞的作用。最后构建肺癌异种移植肿瘤模型,发现EXO蛋白MUC1在体内促进肺癌肿瘤生长,而ICAM1干扰抑制肿瘤生长。综上所述,MUC1富集于tCAFs衍生的exo中,并通过调节icam1介导的线粒体从tCAFs向癌细胞的转移来促进NSCLC的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
5.60%
发文量
142
审稿时长
4-8 weeks
期刊介绍: Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信